Alex Grabowski represents clients in complex patent litigation, with particular emphasis on pharmaceutical and life sciences patent litigation and claims arising under the Hatch-Waxman Act.

Alex draws on his background in chemical engineering and litigation experience to help clients navigate all stages of litigation from pre-suit assessments through trial and appeals. Alex has particular experience representing branded pharmaceutical companies in Hatch-Waxman and brand-on-brand litigations. As part of this, Alex has worked with a variety of pharmaceutical patent portfolios covering everything from compounds and polymorphs to formulations and methods of treatment.

In addition to his pharmaceutical work, Alex also has experience litigating a diverse array of other technologies including process chemistry, medical devices, consumer products, and electromechanical devices.

At his prior firm, Alex also handled patent prosecution and brings unique insights from that experience to bear for his clients, both during litigation and in helping clients evaluate their portfolios.

He also maintains an active pro bono practice, including successfully representing clients in asylum proceedings in immigration court, as well as prisoners in § 1983 cases.

Alex’s experience includes representing:

  • An innovator pharmaceutical company in a series of patent litigations involving a novel narcolepsy drug formulation. Successfully obtained a ruling ordering delisting of an asserted patent from the Orange Book, which was affirmed by the Federal Circuit on appeal; recognized as LMG Life Sciences’ 2025 Impact Case of the Year
  • A brand-side pharmaceutical company in securing a verdict of infringement after a bench trial in Hatch-Waxman litigation related to patents on its epinephrine product
  • A brand-side pharmaceutical company in Hatch-Waxman litigation involving efforts by multiple generic manufacturers to market a generic equivalent to oncology product. After a seven-day bench trial, the court upheld the validity of all claims in all five patents. The Federal Circuit affirmed
  • A brand-side pharmaceutical company in Hatch-Waxman litigation concerning its innovative glaucoma treatment, ultimately securing settlement on favorable terms
  • A pharmaceutical company in securing a preliminary injunction and settlement after seeking to enjoin the state of Nevada from using its products in lethal injection
  • A process chemistry company in securing sanctions and a settlement following accusations of patent infringement by a competitor*
  • A pharmaceutical company in securing a judgment of non-infringement following accusations of patent infringement*

*Matter handled prior to joining Latham

Bar Qualification

  • Illinois
  • US Patent and Trademark Office

Education

  • JD, University of Chicago Law School, 2015
    Online Content Editor, The Chicago Journal of International Law, with honors
  • BS in Chemical Engineering, Northwestern University, 2012
    Dean’s List, Omega Chi Epsilon